Cure8 research brief
Patients with CGD can develop an IBD-like condition that is hard to treat because many immunosuppressive drugs raise infection risk. This trial suggests thalidomide may reduce intestinal inflammation in CGD-IBD without increasing infections in a small group of patients.
For families and clinicians caring for children with CGD-IBD, the study points to a potential therapeutic option that could be studied further.
Pediatric patients with CGD-IBD and their parents/caregivers; clinicians treating CGD-IBD; researchers interested in therapies for rare immune-deficiency–associated IBD; clinicians considering non–anti-TNF options for difficult-to-treat IBD-like disease.
The trial focuses on CGD-IBD, a rare IBD-like condition occurring in patients with chronic granulomatous disease. Thalidomide was tested because of its anti-inflammatory and immunomodulatory effects and a hypothesized lower risk of increasing serious infections compared with conventional immunosuppressants or anti-TNF biologics.
The study is small (8 patients), multicenter, and randomized with a 12-week blinded phase followed by a 12-week extension on thalidomide. The reported results show some patients achieving remission or meaningful improvement on a pediatric disease activity index, and exploratory endoscopy and secondary endpoints reportedly improved.
Infection rates were reported as comparable before and after treatment in this small cohort. The article concludes that thalidomide showed potential efficacy and an acceptable safety profile in CGD-IBD and that further studies are warranted.
Small sample size (8 patients) and single rare-disease population limit generalizability. Thalidomide has significant known safety risks (noted in the literature); this study’s population was all male and majority pediatric. The trial is phase II and exploratory — further larger studies are needed before changing routine care.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Disclosures: T. Kawai reported personal fees from Novartis Pharma K.K., Takeda Pharmaceutical Company Limited, and Asahi Kasei Pharma Corporation outside the submitted work. K. Arai reported grants from Janssen Pharmaceutical K.K., Bristol-Myers Squibb Company, Eli Lilly Japan K.K., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., AbbVie GK, Nobelpharma Co., Ltd., EA Pharma Co., Ltd., and Zeria Pharmaceutical Co., Ltd., and personal fees from Janssen Pharmaceutical K.K., Eli Lilly Japan K.K., Takeda Pharmaceutical Co., Ltd., AbbVie GK, Nobelpharma Co., Ltd., EA Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Alfresa Pharma Corporation outside the submitted work; in addition, K. Arai had a patent number 7738832 licensed “Nobelpharma Co., Ltd.” E. Inoue reported personal fees from Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippontect Systems Co., Ltd., and Cyberdyne Inc. outside the submitted work. H. Nakamura reported grants from Ministry of Health, Labour and Welfare and Japan Agency for Medical Research and Development, and personal fees from FELIQS, Pfizer R&D Japan G.K., Japan Pharmaceutical Manufacturers Association, Sobi Japan, Sato Pharmaceutical Co., Ltd., and Taisho Pharmaceutical Co., Ltd., during the conduct of the study. No other disclosures were reported.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
This case report describes successful use of vedolizumab to treat severe UC in a patient who also had PSC and SLE — a rare and complex combination. Patients and clinicians may find it relevant when considering biologic...
